Information Provided By:
Fly News Breaks for April 20, 2016
SRPT, CVRS, BATS, ALDR, ORCL
Apr 20, 2016 | 10:23 EDT
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Oracle (ORCL) initiated with an Outperform at Northland. 2. Alder Biopharmaceuticals (ALDR) initiated with a Buy at Brean Capital by analyst Jonathan Aschoff, who expects the company's ALD403 to begin selling for chronic migraine and frequent episodic migraine in 2018 and 2019 in the U.S. and Europe, respectively, and to generate about $1B in global revenue in 2022. 3. BATS Global Markets (BATS) initiated with an Underperform at Raymond James with analyst Patrick O'Shaughnessy saying the company will be challenged to to achieve consistent high-single digit organic revenue growth targets due to lack of organic market share growth and ongoing pricing pressures. 4. Corindus (CVRS) initiated with a Buy at Sterne Agee CRT because the company's CorPath system has been approved by the FDA and " is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit." 5. Sarepta (SRPT) initiated with a Neutral at Janney Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
News For ORCL;ALDR;BATS;CVRS;SRPT From the Last 2 Days
There are no results for your query ORCL;ALDR;BATS;CVRS;SRPT